Covalent Werner helicase inhibitor shows clinical proof-of-concept in Phase I trial

Published Date: 29 Apr 2025

For patients with cancers harboring certain genetic defects, the first-in-class targeted therapy RO7589831, which targets the DNA repair enzyme Werner helicase, demonstrated early signals of efficacy and was generally well-tolerated, ...

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Remote monitoring can improve recovery from cancer surgery

2.

Intractable cancers may respond better to treatment when using new radiation and high-performance computing.

3.

A Win for AI in Cancer; 2025's Transformative Drugs; FDA Clarifies 'Underway' Trials

4.

Conditional EU Nod for Weekly Pill in Pediatric Glioma

5.

high response rate when using a bispecific antibody to treat R/R multiple myeloma.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot